G1 Therapeutics

General Information

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. Our two clinical assets are based on our core understanding of cyclin-dependent kinases, or CDKs, a family of proteins that play an important role in the growth and proliferation of all human cells. Two particular CDKs, CDK4 and CDK6, collectively known as CDK4/6, represent a validated and promising class of targets for anti-cancer therapeutics.

Employees: 30
Founded: 2008
Contact Information
Address 79 T.W. Alexander Drive, 4501 Research Commons, Suite 100, Research Triangle Park, NC 27709, US
Phone Number (919) 213-9835
Web Address http://www.g1therapeutics.com
View Prospectus: G1 Therapeutics
Financial Information
Market Cap $411.0mil
Revenues $0 mil (last 12 months)
Net Income $-44.5 mil (last 12 months)
IPO Profile
Symbol GTHX
Exchange NASDAQ
Shares (millions): 7.0
Price range $15.00 - $15.00
Est. $ Volume $105.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen and Company
CO-Managers Needham & Company/ Wedbush PacGrow
Expected To Trade: 5/17/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change